Craft
Eutilex

Eutilex

Revenue

₩73.5 M

FY, 2021

Market Capitalization

₩55.6 B

2022-08-19

Eutilex Summary

Company summary

Overview
Eutilex ((주)유틸렉스) is a biotech company developing anti-tumor T-cell therapy. Additionally, it offers antibody therapeutics based on its proprietary immunotherapy technology.
Type
Public
Status
Active
Founded
2015
HQ
KR | view all locations
Website
http://eutilex.com/en/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Byoung S. Kwon

    Byoung S. Kwon, CEO

    • Soo Young Choi

      Soo Young Choi, COO

      • Edwin E. Kwon

        Edwin E. Kwon, CFO

        • Jeonghoon Han

          Jeonghoon Han, CBO

          LocationsView all

          1 location detected

          • Seoul HQ

            Korea (Republic of)

            25 Gasan digital 1-ro, Geumcheon-gu

          Eutilex Financials

          Summary financials

          Revenue (Q1, 2022)
          ₩22.3M
          Gross profit (Q1, 2022)
          ₩23.2M
          Net income (Q1, 2022)
          (₩8.5B)
          Cash (Q1, 2022)
          ₩51.4B
          EBIT (Q1, 2022)
          (₩8.6B)
          Enterprise value
          $29.3B

          Footer menu